Over the past seven years, Dr. Fischer has been active with clinical research projects relevant to rheumatologic lung disease. He has led multiple original clinical research projects involving connective tissue disease-related interstitial lung disease that have resulted in a number of first-authorship publications in peer-reviewed journals and numerous abstracts relevant to rheumatologic lung disease presented at annual American Thoracic Society or American College of Rheumatology meetings.

Dr. Fischer has been active as an investigator in clinical trials as well. He is the National Jewish Health site Principal Investigator for “Scleroderma Lung Study II” – a multi-institutional, NIH-funded, clinical trial for the treatment of scleroderma associated interstitial lung disease. He is also the site Principal Investigator for “PHAROS”, a national, multi-institutional scleroderma registry for patients at increased risk for the development of pulmonary arterial hypertension.

Ongoing Clinical Trials and Registries:

  • Scleroderma Lung Study II: Mycophenolate Mofetil vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease

  • PHAROS: The Natural History and Outcome of Scleroderma Patients at High Risk or with Early Pulmonary Hypertension


Learn more about the Division of Rheumatology.